Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 ...

Kids with Duchenne muscular dystrophy and their families deserve the chance to decide their own future.

Genethon, a pioneer and leader in gene therapy for rare diseases, unveiled results at the MDA Conference in Orlando confirming the long-term efficacy of its GNT0004 gene therapy in Duchenne muscular ...

Friends and family of Sophie Hutchison, who was diagnosed with limb girdle muscular dystrophy at 13, will take part in this year's Kiltwalk to raise money for Muscular Dystrophy UK.

Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022)Significant improvement in LVEF versus placebo in patients ...

Detailed price information for Benitec Biopharma Ltd ADR (BNTC-Q) from The Globe and Mail including charting and trades.

Regenxbio's gene therapy shows promise for Duchenne muscular dystrophy, Eli Lilly invests $3 billion in China for diabetes treatment, and China approves a brain-computer interface device. CVS' Aetna ...

The MarketWatch News Department was not involved in the creation of this content. PARAMUS, N.J., March 9, 2026 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma, New Jersey, USA; President, Yukiteru Sugiyama ...

Benitec Executive Chairman and Chief Executive Officer, Jerel A. Banks, M.D., Ph.D., will share an updated presentation detailing the significant, durable, improvements in dysphagic symptom burden and ...

Solid Biosciences (SLDB) stock retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne ...

Sophie Hutchison’s condition means she she struggles with 'simple' tasks such as climbing stairs or even lifting her arms.

Data from BridgeBio Pharma’s Phase 3 FORTIFY study show that BBP-418 significantly increases levels of a key disease biomarker that helps stabilize muscles in patients with limb-girdle muscular ...